In a mouse CML model, the BIM/MCL-1 ChNPs and dasatinib combination therapy suppressed proliferation of BCR-ABL + hematopoietic cells and prevented leukemic infiltration of organs. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.